Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MDBH
MDBH logo

MDBH Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
3.470
Open
3.330
VWAP
3.47
Vol
--
Mkt Cap
34.24M
Low
3.470
Amount
--
EV/EBITDA(TTM)
--
Total Shares
10.44M
EV
19.14M
EV/OCF(TTM)
--
P/S(TTM)
8.10
MDB Capital Holdings, LLC is a holding company that has three subsidiaries: MDB CG Management Company (MDB Management), Public Ventures, LLC (Public Ventures), and PatentVest, Inc. (PatentVest), and has a partner company, MDB Minnesota One, Inc. Its segments include broker dealer & intellectual property service, and technology development. The broker dealer & intellectual property service segment has two subsidiaries, Public Ventures and PatentVest. Public Ventures is a full-service broker dealer firm focusing on conducting private and public securities offerings. PatentVest offers in-depth patent research used for investment banking due diligence. The technology development segment includes MDB Minnesota One, Inc., a research and development stage company that is developing a small molecule senescence platform. MDB Management is an administrative entity whose purpose is to conduct, and wherever possible, to consolidate shared services/resources, for its United States-based operations.
Show More

Events Timeline

(ET)
2025-06-02
17:54:11
MDB Capital announces board transitions
select
2025-05-27 (ET)
2025-05-27
16:12:20
ClearSign Board to expand in size to seven directors
select
2025-05-21 (ET)
2025-05-21
09:04:20
MDB Capital provides Q1 update, continued to work on new opportunities
select
2025-02-21 (ET)
2025-02-21
16:07:58
eXoZymes president, chairman Hayat transitions out of roles
select

News

Newsfilter
3.5
07-02Newsfilter
Patent Prosecution Ready for AI Integration
  • Transformation in Legal Services: PatentVest's new article discusses how AI is poised to revolutionize patent prosecution, highlighting its potential to significantly enhance efficiency and quality through structured workflows and standardized processes.
  • Enhanced Strategic Value: The article emphasizes that AI's greatest value lies in enabling patent professionals to spend less time on repetitive tasks, thereby allowing more focus on strategic legal judgment, which will improve overall patent management effectiveness and alignment with business objectives.
  • Integration of Technology and Human Expertise: While AI plays an increasingly vital role in patent prosecution, the article stresses that experienced patent attorneys remain essential for protecting innovation and aligning IP with business goals, underscoring the importance of human-machine collaboration.
  • Future Competitive Advantage: PatentVest COO Javier Chamorro notes that understanding where AI adds value in patent practice and where human expertise remains indispensable will provide companies with a significant advantage in future competition, especially when building AI-driven patent strategies.
Newsfilter
7.5
06-30Newsfilter
FGF21 Reshaping Obesity Therapeutics Landscape
  • Strategic Shift: The PatentVest report highlights over $10.7 billion in acquisitions and licensing activities in the FGF21 space, indicating growing confidence among pharmaceutical companies in FGF21 as the next major opportunity beyond GLP-1, potentially driving a new wave of obesity treatment innovations.
  • Enhanced Competitive Layer: FGF21 is being developed alongside GLP-1 therapies to address broader cardiometabolic diseases such as liver disease and chronic inflammation, showcasing its significance and potential in the obesity treatment landscape.
  • Market Competitive Analysis: The report provides a detailed analysis of the companies, clinical programs, and strategic positioning within the emerging FGF21 market, aiding industry participants in identifying key competitors and collaboration opportunities to optimize their market strategies.
  • Intellectual Property Strategy: PatentVest explores how combination therapies and platform technologies may influence long-term competitive positioning in obesity therapeutics, emphasizing the critical role of intellectual property in maintaining competitive advantages in a rapidly evolving market.
Newsfilter
1.0
06-15Newsfilter
PatentVest to Present at Planet MicroCap Conference
  • IP Strategy Transformation: PatentVest will discuss at the Planet MicroCap conference on June 17 how to transform intellectual property from a legal function into a strategic asset that supports enterprise value creation, likely attracting attention from innovation-driven companies.
  • AI-Driven Service Vision: The firm will showcase its AI-native workflows and outcome-based patent prosecution methodologies designed to enhance efficiency and patent quality, thereby supporting scalable portfolio growth to meet modern business demands.
  • Increased Industry Transparency: COO Javier Chamorro emphasized that AI will bring unprecedented transparency to intellectual property, enforcing real accountability in legal services and changing how patents are drafted to meet real-time scrutiny requirements.
  • Investor Engagement Opportunities: Throughout the conference, PatentVest leadership will engage with investors and corporate executives, providing in-depth discussions on portfolio strategy and intellectual property intelligence, further enhancing the company's market influence.
Newsfilter
2.0
06-04Newsfilter
Muscle Preservation Therapies Create New Opportunities in Obesity Treatment
  • Emerging Category Growth: Analysis reveals that there are currently 20 muscle-preservation programs in development, indicating a growing industry investment aimed at enhancing obesity treatment outcomes, which could drive rapid market expansion.
  • Strategic Transaction Analysis: Major moves such as Eli Lilly's acquisition of Versanis Bio and AstraZeneca's acquisition of SixPeaks Bio reflect increasing confidence in muscle-preservation therapies, potentially leading to more collaborations and investments.
  • Combination Therapy Opportunity: Findings suggest that muscle-preservation therapies are not intended to replace GLP-1s but rather to enhance their long-term value through improved body composition and patient outcomes, potentially reshaping the obesity treatment landscape.
  • Intellectual Property Positioning: Patent analysis indicates that as muscle-preservation therapies mature, patents related to GLP-1 combination therapies, method-of-use claims, and pathway-specific intellectual property will become increasingly important, potentially providing new competitive advantages for companies.
Newsfilter
7.5
05-08Newsfilter
Analysis of Global Triple-Agonist Drug Market
  • Competitive Landscape: PatentVest's report highlights that industry leaders such as Eli Lilly, Novo Nordisk, Pfizer, Roche, and Sanofi, along with emerging players like Hanmi Pharmaceutical and Innovent Biologics, are fiercely competing to dominate the next generation of obesity therapeutics, indicating an intensifying competitive environment.
  • Global Pipeline Expansion: The report identifies 27 triple-agonist programs, with China playing a significant role in development activities, signaling a shift in global innovation dynamics and potential future licensing opportunities in the obesity drug market.
  • Intellectual Property Dynamics: Patent analysis reveals a transition in competitive advantage drivers from receptor discovery to receptor-ratio engineering, formulation control, delivery systems, and method-of-use claims, underscoring the critical role of intellectual property in shaping future market landscapes.
  • Strategic Positioning: Findings suggest that companies like Sanofi, despite lacking visible clinical programs, may possess significant latent IP positions that could influence the future market structure, emphasizing the strategic importance of controlling intellectual property.
Newsfilter
5.0
04-29Newsfilter
Eli Lilly's Retatrutide Redefines Weight Loss Market
  • Weight Loss Breakthrough: Eli Lilly's retatrutide achieved a mean weight loss of 28.7% in April 2026, becoming the first non-surgical therapy to match bariatric outcomes, marking a significant advancement in weight loss treatment.
  • Intensified Market Competition: Following the success of retatrutide, companies like Novo Nordisk, Pfizer, and Hanmi are ramping up their R&D efforts to capture market share, highlighting the industry's keen focus on controlling intellectual property.
  • Intellectual Property Strategy: PatentVest emphasizes that the future competition will pivot towards who can effectively manage IP and who can secure market advantages, underscoring the critical role of intellectual property in drug development.
  • Clinical Results vs. Real-World Outcomes: Despite the impressive 28.7% weight loss in clinical trials, PatentVest warns of potential discrepancies in real-world effectiveness, suggesting that future competition will center on bridging this gap.

Valuation Metrics

The current forward P/E ratio for MDB Capital Holdings LLC (MDBH.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess MDB Capital Holdings LLC's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

con rentabilidad alta a corto plazo
Intellectia · 61 candidates
Price: <= $20.00Quarter Revenue Yoy Growth: >= 20.0%Quarter Eps Yoy Growth: >= 15.0%Relative Vol: >= 1.50
Ticker
Name
Market Cap$
top bottom
RBKB logo
RBKB
Rhinebeck Bancorp Inc
134.53M
BZAI logo
BZAI
Blaize Holdings Inc
255.60M
XLO logo
XLO
Xilio Therapeutics Inc
40.33M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
566.90M
IBRX logo
IBRX
Immunitybio Inc
6.82B
MDBH logo
MDBH
MDB Capital Holdings LLC
33.86M

Whales Holding MDBH

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is MDB Capital Holdings LLC (MDBH) stock price today?

The current price of MDBH is 3.47 USD — it has increased 5.79

What is MDB Capital Holdings LLC (MDBH)'s business?

MDB Capital Holdings, LLC is a holding company that has three subsidiaries: MDB CG Management Company (MDB Management), Public Ventures, LLC (Public Ventures), and PatentVest, Inc. (PatentVest), and has a partner company, MDB Minnesota One, Inc. Its segments include broker dealer & intellectual property service, and technology development. The broker dealer & intellectual property service segment has two subsidiaries, Public Ventures and PatentVest. Public Ventures is a full-service broker dealer firm focusing on conducting private and public securities offerings. PatentVest offers in-depth patent research used for investment banking due diligence. The technology development segment includes MDB Minnesota One, Inc., a research and development stage company that is developing a small molecule senescence platform. MDB Management is an administrative entity whose purpose is to conduct, and wherever possible, to consolidate shared services/resources, for its United States-based operations.

What is the price predicton of MDBH Stock?

Wall Street analysts forecast MDBH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDBH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is MDB Capital Holdings LLC (MDBH)'s revenue for the last quarter?

MDB Capital Holdings LLC revenue for the last quarter amounts to 44.00K USD, decreased -94.69

What is MDB Capital Holdings LLC (MDBH)'s earnings per share (EPS) for the last quarter?

MDB Capital Holdings LLC. EPS for the last quarter amounts to -0.66 USD, decreased -0.00

How many employees does MDB Capital Holdings LLC (MDBH). have?

MDB Capital Holdings LLC (MDBH) has 14 emplpoyees as of July 08 2026.

What is MDB Capital Holdings LLC (MDBH) market cap?

Today MDBH has the market capitalization of 34.24M USD.